Posted by Michael Wonder on 15 Mar 2024
Bimzelx (bimekizumab) now approved for adults with active psoriatic arthritis and for adults with axial spondyloarthritis
14 March 2024 - Health Canada's approval is supported by Phase III clinical trial data which found Bimzelx provided significant improvement across key disease severity indicators.
Today, UCB Canada is pleased to announce that Bimzelx (bimekizumab) has received authorisation from Health Canada for two new indications. On 23 February 2024, Bimzelx was approved for the treatment of adults with active psoriatic arthritis and on 11 March 2024, the therapy also received approval for the treatment of adults with axial spondyloarthritis.
